cbdMD, Inc. (YCBD) Key Metrics
YCBD valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $4.0M
- Enterprise value
- $5.2M
- P/E (TTM)
- 1.5
- Forward P/E
- 714.3
- PEG ratio
- —
- Price / sales
- 0.2
- Price / book
- 0.6
- EV / EBITDA
- 63.9
- Dividend yield
- —
- Beta
- 2.25
YCBD key metrics, FY2016–FY2025
Fiscal year ended September 30, 2025 · U.S. dollarsYCBD valuation Price multiples at each fiscal year-end price.
YCBD returns How much profit the business earns on the capital it uses.
YCBD per-share figures Results divided by the shares outstanding at year-end.
YCBD financial health Debt, liquidity and how easily interest is covered.
YCBD efficiency & capital use Working capital cycle and where the cash goes.
YCBD valuation history
YCBD returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
YCBD debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
YCBD cash returned to shareholders
YCBD price vs earnings per share
YCBD key metrics
FY2016–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $4.9M | $16.2M | — | — | — | — | — | — | — | — |
| Enterprise value | $780.8M | $15.0M | — | — | — | — | — | — | — | — |
| Price / sales | 0.3 | 0.8 | — | — | — | — | — | — | — | — |
| Price / book | 0.7 | 8.3 | — | — | — | — | — | — | — | — |
| EV / sales | 40.7 | 0.8 | — | — | — | — | — | — | — | — |
| Earnings yield | −41.9% | −22.8% | — | — | — | — | — | — | — | — |
| Free cash flow yield | −33.6% | −4.0% | — | — | — | — | — | — | — | — |
| Dividend yield | — | 0.0% | — | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | 0.0% | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $1.21 | $3.76 | $8.28 | $81.04 | $748.80 | $720.00 | $1,425.60 | $1,306.80 | — | — |
| Per share | ||||||||||
| Revenue per share | $4.77 | $4.52 | — | — | — | — | — | — | — | — |
| Earnings per share | −$0.51 | −$0.86 | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$0.36 | −$0.08 | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$0.41 | −$0.15 | — | — | — | — | — | — | — | — |
| Cash per share | $0.56 | $0.57 | — | — | — | — | — | — | — | — |
| Book value per share | $1.80 | $0.46 | — | — | — | — | — | — | — | — |
| Tangible book value per share | $1.27 | −$0.21 | — | — | — | — | — | — | — | — |
| Dividends per share | — | $0.00 | — | — | — | — | — | — | — | — |
| Capex per share | $0.05 | $0.07 | — | — | — | — | — | — | — | — |
| Debt per share | $193.47 | $0.29 | — | — | — | — | — | — | — | — |
| Shares outstanding | 4.0M | 4.3M | — | — | — | — | — | — | — | — |
| Change in shares outstanding | −6.7% | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −44.4% | −67.3% | −113.4% | −104.2% | −25.7% | 21.6% | −200.9% | −4.9% | −76.0% | −382.0% |
| Return on invested capital (ROIC) | −0.4% | −43.1% | −37.1% | −24.8% | −20.1% | −33.5% | −59.0% | −29.8% | −8.3% | −255.9% |
| Return on assets (ROA) | −19.4% | −27.6% | −80.5% | −84.6% | −19.8% | 12.3% | −92.1% | −3.7% | −40.0% | −194.8% |
| Return on tangible assets | −24.6% | −48.1% | −176.8% | −305.3% | −51.9% | 36.5% | −276.9% | −3.5% | −45.4% | −295.3% |
| Free cash flow margin | −8.5% | −3.3% | −19.0% | −44.2% | −36.9% | −28.6% | −70.3% | — | −52.2% | −148.9% |
| Income quality (OCF / net income) | — | — | — | — | — | −0.85 | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $778.2M | $1.3M | $3.7M | $4.9M | $6.1M | $8.7M | $194,466 | — | $360,000 | $797,547 |
| Cash & short-term investments | $2.3M | $2.5M | $1.8M | $7.7M | $27.4M | $15.1M | $5.5M | $6.5M | $1.1M | $34,258 |
| Net debt | $776.0M | −$1.2M | $1.9M | −$2.9M | −$21.4M | −$6.4M | −$5.3M | −$6.5M | −$783,358 | $763,289 |
| Debt / equity | 107.70 | 0.65 | 0.41 | 0.15 | 0.06 | 0.11 | 0.01 | — | 0.09 | 2.19 |
| Debt / assets | 74.69 | 0.12 | 0.23 | 0.12 | 0.05 | 0.08 | 0.00 | — | 0.05 | 0.49 |
| Current ratio | 2.05 | 0.74 | 1.73 | 3.03 | 5.28 | 3.08 | 4.24 | 12.16 | 2.42 | 0.50 |
| Quick ratio | 1.13 | 0.47 | 0.86 | 2.22 | 4.55 | 2.45 | 3.08 | 12.03 | 2.04 | 0.14 |
| Interest coverage | — | -108.1 | — | — | -678.1 | -0.3 | -0.2 | — | -0.5 | -24.1 |
| Working capital | $3.4M | −$2.2M | $3.4M | $10.7M | $29.6M | $16.0M | $12.0M | $10.8M | $2.2M | −$947,766 |
| Invested capital | $783.2M | $780,868 | $10.9M | $28.6M | $81.8M | $72.8M | $32.3M | $6.1M | $3.4M | $1.1M |
| Tangible asset value | $5.1M | −$926,163 | $5.8M | $13.6M | $23.4M | $2.9M | −$38.7M | $10.8M | $1.9M | −$779,485 |
| Net current asset value | $3.4M | −$2.2M | $906,042 | $6.6M | $14.8M | −$7.9M | −$41.2M | $10.8M | $1.8M | −$959,766 |
| Graham net-net per share | $0.33 | −$0.98 | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | $0 | $3.7M | $4.0M | $2.6M | $366,850 | $366,850 | $366,850 | $29,180 | — |
| Share buybacks (net) | — | — | $0 | — | $30.8M | $1.5M | $0 | $0 | $0 | $0 |
| Dividend payout ratio | — | — | — | — | — | 2.9% | — | — | — | — |
| Capex / revenue | 1.0% | 1.5% | 1.2% | 1.9% | 5.3% | 3.2% | 5.3% | 83.5% | 0.2% | 6.3% |
| Capex / depreciation | 0.10 | 0.16 | 0.10 | 0.23 | 1.04 | 1.83 | 4.31 | 1.72 | 0.11 | 2.83 |
| Stock-based compensation / revenue | 0.1% | 0.1% | 1.4% | 2.6% | 6.6% | 4.9% | 11.4% | 147.8% | 4.8% | 0.6% |
| R&D / revenue | 0.2% | 0.2% | 0.7% | 1.8% | 3.2% | 1.0% | — | — | — | — |
| SG&A / revenue | 59.6% | 64.8% | 75.1% | 88.3% | 88.4% | 83.4% | 122.1% | 420.3% | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 19.3 | 20.6 | 20.1 | 13.2 | 8.3 | 15.6 | 53.0 | 2,219.7 | 62.9 | 14.7 |
| Days of inventory on hand | 134.2 | 135.6 | 136.4 | 113.6 | 116.6 | 108.1 | 88.4 | 397.6 | 171.8 | 96.4 |
| Days payables outstanding | 68.6 | 72.8 | 64.7 | 61.4 | 68.6 | 69.1 | 70.0 | 529.3 | 90.4 | 32.4 |
| Cash conversion cycle (days) | 84.9 | 83.4 | 91.8 | 65.4 | 56.4 | 54.7 | 71.4 | 2,088.0 | 144.3 | 78.8 |
| Receivables turnover | 18.96 | 17.71 | 18.14 | 27.65 | 43.93 | 23.42 | 6.88 | 0.16 | 5.80 | 24.76 |
| Payables turnover | 5.32 | 5.01 | 5.64 | 5.94 | 5.32 | 5.28 | 5.22 | 0.69 | 4.04 | 11.28 |
| Inventory turnover | 2.72 | 2.69 | 2.68 | 3.21 | 3.13 | 3.38 | 4.13 | 0.92 | 2.12 | 3.78 |
| Asset turnover | 1.83 | 1.46 | 0.85 | 0.43 | 0.38 | 0.41 | 0.43 | 0.04 | 1.03 | 1.18 |
| Average receivables | $1.0M | $1.1M | $1.3M | $1.3M | $1.0M | $1.8M | $3.4M | $2.8M | $771,470 | $82,062 |
| Average payables | $1.4M | $1.7M | $2.0M | $2.5M | $2.9M | $2.9M | $1.8M | $473,528 | $335,818 | $143,524 |
| Average inventory | $2.7M | $3.2M | $4.2M | $4.6M | $5.0M | $4.6M | $2.2M | $355,710 | $637,831 | $427,595 |
| Intangibles / total assets | 20.4% | 27.3% | 19.9% | 43.7% | 63.9% | 68.8% | 80.7% | 21.1% | 45.8% | 30.0% |
Computed from YCBD's annual financial statements (latest annual report filed December 19, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
YCBD valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 1.5 and the forward P/E is 714.3. cbdMD earned a return on equity of −44.4% and a return on invested capital of −0.4% in fiscal 2025. It ended the year with $778.2 million of debt and $2.3 million in cash and short-term investments, net debt of $776.0 million.
See the YCBD income statement, the YCBD chart for price history, or the YCBD stock overview for the latest quote and news.
YCBD key metrics FAQ
What is cbdMD's P/E ratio?
cbdMD's trailing P/E ratio is 1.5 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 714.3. At the end of fiscal 2025 it was —.
What is cbdMD's return on equity?
cbdMD's return on equity (ROE) was −44.4% in fiscal 2025: net income of -$2.0 million on average shareholders' equity of $4.6 million.
What is cbdMD's ROIC?
cbdMD's return on invested capital was −0.4% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does cbdMD have?
cbdMD had total debt of $778.2 million at the end of fiscal 2025, a debt-to-equity ratio of 107.70.
What is cbdMD's free cash flow yield?
cbdMD generated -$1.6 million of free cash flow in fiscal 2025, a free cash flow yield of −33.6% on its market value at year-end ($4.9 million).
What is cbdMD's current ratio?
cbdMD's current ratio was 2.05 at the end of fiscal 2025: current assets were 2.05 times current liabilities.